Neurology faculty answer questions about Amyotrophic Lateral Sclerosis (ALS) and Glioblastoma (GBM)
Pictured (left to right): Jinsy Andrews, MD, MSc, Matthew B. Harms, MD, and Laura E. Donovan, MD.
Department of Neurology's faculty -- Jinsy A. Andrews, MD, MSc, FAAN, Matthew B. Harms, MD, and Laura E. Donovan, MD, answer questions posed by people navigating complex health conditions conserning amyotrophic lateral sclerosis (ALS) and Glioblastoma (GBM) on Roon.com.
Amyotrophic Lateral Sclerosis (ALS)
Jinsy A. Andrews, MD, MSc, FAAN is an Associate Professor of Neurology, in the Division of Neuromuscular Medicine and serves as the Director of Neuromuscular Clinical Trials at Columbia University Irving Medical Center. Dr. Andrews currently oversees neuromuscular clinical trials and cares for patients with neuromuscular disease, primarily with ALS. [read Dr. Andrews' answers]
Matthew B. Harms, MD is an Associate Professor of Neurology in the Division of Neuromuscular Medicine and Division of Clinical Neurophysiology. Dr. Harms' research is in understanding the genetic underpinnings of the the disease and in developing treatments to target those root causes. He is focused on uncovering the genetic mutations that increase the risk of developing ALS or contribute to how fast the disease progresses. He is the Chair of the ClinGen ALS Gene and Variant Curation teams and has studied the genes of >12,000 people with ALS. [read Dr. Harms' answers]
Glioblastoma (GBM)
Laura E. Donovan, MD is an Assistant Professor of Neurology at CUIMC in the Division of Neuro-Oncology. Dr. Donovan's research interests include improving care delivery and identifying interventions to improve quality of life in patients with primary and metastatic brain tumors.[read Dr. Donovan's answers]